Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021
- Expanded Phase 2 data set continues to provide compelling rationale for move to registrational clinical program - - Bomedemstat demonstrated durable clinical improvement in patients with ET who... | December 12, 2021
United States New Zealand United Kingdom South San Francisco Hugh Young Rienhoff Jr Francesca Palandri
Source: marketscreener.com